Anzeige
Mehr »
Login
Dienstag, 07.05.2024 Börsentäglich über 12.000 News von 687 internationalen Medien
Diese Aktie hebt ab: +130,67% Kursgewinn in 1 Monat – das sind die Gründe
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
424 Leser
Artikel bewerten:
(2)

Apollo Proton Cancer Centre Receives Prestigious JCI Accreditation

CHENNAI, India, July 3, 2020 /PRNewswire/ -- Apollo Proton Cancer Centre (APCC), the first Proton Therapy Centre in South Asia and the Middle East, announced its accreditation by Joint Commission International (JCI), the recognized global leader in health care accreditation. This makes APCC the first dedicated advanced cancer centre to receive this international accreditation. Since its commencement in June 2019, APCC has been the preferred cancer centre globally for Proton Therapy and Cancer Care Management. JCI accreditation is the gold standard in following global practices for exceptional patient care and safety.

The Dream team behind getting the Golden Seal from JCI for Apollo Proton Cancer Center, India

Dr. Prathap C Reddy, Chairman, Apollo Hospitals, said, "The growing prevalence of cancer in India with the lack of Oncology centres led to our bringing in the most advanced technologies in cancer care culminating in South Asia and Middle East's first Proton Therapy Centre. The top 10 Cancer care specialists are working with us, equipped with advanced ultramodern medical technology to ensure our center is a world-class proton care center. It is a matter of pride that APCC is now recognised for its quality standards which will further strengthen our resolve to keep raising the bar in Oncology."

Paula Wilson, President and CEO, JCI, said, "Joint Commission International (JCI) commends APCC for its commitment to meeting international quality and patient safety standards by earning JCI accreditation during the global pandemic. This achievement was possible by utilizing JCI's virtual survey process, where surveys are conducted through the use of technology."

Ms. Preetha Reddy, Vice Chairperson, Apollo Hospitals, said, "APCC has succeeded in making the world's most advanced radiation therapy accessible to benefit a large population. The first Proton Therapy Centre to receive the gold standard JCI accreditation in South Asia and Middle East, this milestone was achieved despite the challenges posed by the pandemic, which underscores the APCC's commitment to quality and advanced patient care."

In its first year of operation, APCC has already performed over 200 proton procedures and over 750 surgical procedures on patients from across the globe. Multi-disciplinary Disease Management Groups and personalised organ-specific care plans ensures that patients feel safe, comfortable and receive the epitome of personalized oncology care during their cancer treatment.

About Apollo Proton Cancer Centre

A beacon of excellence, APCC is the first in India to introduce Proton Therapy. A fully integrated treatment facility offering advanced surgical, radiation, and medical oncology treatment.

https://proton.apollohospitals.com/

Contact:
Saurabh Bose
saurabh_bose@apollohospitals.com
+91(0)402-360-7777

Logo: https://mma.prnewswire.com/media/1200114/Apollo_Proton_Cancer_Centre_Logo.jpg
Photo: https://mma.prnewswire.com/media/1200113/APCC_Team.jpg

Apollo_Proton_Cancer_Centre_Logo
Kupfer - Jetzt! So gelingt der Einstieg in den Rohstoff-Trend!
In diesem kostenfreien Report schaut sich Carsten Stork den Kupfer-Trend im Detail an und gibt konkrete Produkte zum Einstieg an die Hand.
Hier klicken
© 2020 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.